Evidence map›Paper›PMID 34764236›Full record

ArticleCell death & disease2021

Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.

Kathryn Davidson, Paul Grevitt, Maria F Contreras-Gerenas, Katherine S Bridge, Miguel Hermida, Kunal M Shah, Faraz K Mardakheh, Mark Stubbs, Rosemary Burke, Pedro Casado and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. ClonalLife science alliance · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kathryn Davidson *Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK.
Paul Grevitt *Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK.ORCID http://orcid.org/0000-0001-8224-1315
Maria F Contreras-GerenasBarts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK.ORCID http://orcid.org/0000-0001-6239-5325
Katherine S BridgeYork Biomedical Research Institute, University of York, Wentworth Way, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0003-1516-1459
Miguel HermidaDepartment of Bioengineering, Imperial College, London, UK.
Kunal M ShahBarts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK.ORCID http://orcid.org/0000-0002-4508-9606
Faraz K MardakhehBarts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK.ORCID http://orcid.org/0000-0003-3896-0827
Mark StubbsCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Rosemary BurkeCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.ORCID http://orcid.org/0000-0002-0011-9701
Pedro CasadoBarts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK.ORCID http://orcid.org/0000-0002-4207-9349
Pedro R CutillasBarts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK.ORCID http://orcid.org/0000-0002-3426-2274
Sarah A MartinBarts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK. sarah.martin@qmul.ac.uk.ORCID http://orcid.org/0000-0003-3321-6601
Tyson V SharpBarts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK. t.sharp@qmul.ac.uk.ORCID http://orcid.org/0000-0003-1861-7984
Queen Mary University of London · GBInstitute of Cancer Research · GBImperial College London · GBUniversity of York · GB

Funding

Cancer Research UK 22897Medical Research Council MR/N009185/1
6 · The paper itself

Abstract

An early event in lung oncogenesis is loss of the tumour suppressor gene LIMD1 (LIM domains containing 1); this encodes a scaffold protein, which suppresses tumorigenesis via a number of different mechanisms. Approximately 45% of non-small cell lung cancers (NSCLC) are deficient in LIMD1, yet this subtype of NSCLC has been overlooked in preclinical and clinical investigations. Defining therapeutic targets in these LIMD1 loss-of-function patients is difficult due to a lack of 'druggable' targets, thus alternative approaches are required. To this end, we performed the first drug repurposing screen to identify compounds that confer synthetic lethality with LIMD1 loss in NSCLC cells. PF-477736 was shown to selectively target LIMD1-deficient cells in vitro through inhibition of multiple kinases, inducing cell death via apoptosis. Furthermore, PF-477736 was effective in treating LIMD1

Indexed as

AnimalsCarcinoma, Non-Small-Cell LungFemaleHumansIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsLung NeoplasmsMiceMice, Inbred NODProof of Concept StudyTransfectionIntracellular Signaling Peptides and ProteinsLimd1 protein, mouseLIM Domain Proteins

Identifiers

PMID34764236
PMCPMC8586256
OpenAlexW3214193395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.